Payment overview · 2025
General Payments
$393.95
21 reported records · 12 companies
Healthcare provider profile · identity verified
Anton Kosov, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CAMDENTON, MO · NPI 1619321817
Verified facts
What the public records show
CMS Open Payments records show Anton Kosov, M.D. received $393.95 in general payments during 2025 across 21 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nucynta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $89.88 | 22.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.26 | 15.8% | 4 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.63 | 11.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.09 | 8.9% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $28.80 | 7.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.94 | 6.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.60 | 6.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.69 | 5.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.11 | 4.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.72 | 4.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.43 | 3.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.80 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $393.95 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.88 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.26 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.26 | 4 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $44.63 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 41 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 163 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 782 | 206 |
| Levothyroxine Sodium | Levothyroxine Sodium | 665 | 182 |
| Lisinopril | Lisinopril | 624 | 178 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 489 | 97 |
| Losartan Potassium | Losartan Potassium | 485 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 479 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 138 |
| Omeprazole | Omeprazole | 464 | 119 |
| Tramadol Hcl | Tramadol Hcl | 442 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 411 | 130 |
| Tamsulosin Hcl | Tamsulosin Hcl | 368 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 96 |
| Metformin Hcl | Metformin Hcl | 342 | 88 |
| Furosemide | Furosemide | 332 | 96 |
| Gabapentin | Gabapentin | 310 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 304 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 292 | 82 |
| Potassium Chloride | Potassium Chloride | 289 | 88 |
| Trazodone Hcl | Trazodone Hcl | 287 | 66 |
| Simvastatin | Simvastatin | 286 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 264 | 52 |
| Sertraline Hcl | Sertraline Hcl | 251 | 63 |
| Alprazolam | Alprazolam | 222 | 50 |
| Allopurinol | Allopurinol | 209 | 55 |
| Montelukast Sodium | Montelukast Sodium | 197 | 52 |
| Pregabalin | Pregabalin | 194 | 31 |
| Eliquis | Apixaban | 163 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 32 |
| Meloxicam | Meloxicam | 159 | 45 |
| Ozempic | Semaglutide | 150 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 45 |
| Carvedilol | Carvedilol | 138 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 136 | 17 |
| Metformin Hcl Er | Metformin Hcl | 133 | 43 |
| Warfarin Sodium | Warfarin Sodium | 133 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 127 | 32 |
| Clonazepam | Clonazepam | 125 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 123 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 36 |
| Famotidine | Famotidine | 113 | 33 |
| Glimepiride | Glimepiride | 112 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 20 |
| Ezetimibe | Ezetimibe | 99 | 29 |
| Glipizide | Glipizide | 99 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 27 |
| Lorazepam | Lorazepam | 96 | 18 |
| Donepezil Hcl | Donepezil Hcl | 95 | 26 |
| Mounjaro | Tirzepatide | 95 | 16 |
| Prednisone | Prednisone | 95 | 63 |
| Baclofen | Baclofen | 89 | 22 |
| Spironolactone | Spironolactone | 89 | 25 |
| Farxiga | Dapagliflozin Propanediol | 88 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 16 |
| Bupropion Xl | Bupropion Hcl | 85 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 82 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 23 |
| Finasteride | Finasteride | 76 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 76 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 72 | 14 |
| Buspirone Hcl | Buspirone Hcl | 71 | 13 |
| Lovastatin | Lovastatin | 67 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 18 |
| Atenolol | Atenolol | 66 | 19 |
| Celecoxib | Celecoxib | 66 | 20 |
| Diazepam | Diazepam | 65 | 16 |
| Ramipril | Ramipril | 64 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 15 |
| Ibuprofen | Ibuprofen | 63 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 61 | 18 |
| Nifedipine Er | Nifedipine | 57 | 17 |
| Synthroid | Levothyroxine Sodium | 57 | 18 |
| Temazepam | Temazepam | 57 | 11 |
| Fenofibrate | Fenofibrate | 55 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 51 | 12 |
| Jardiance | Empagliflozin | 49 | 13 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Xarelto | Rivaroxaban | 47 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 37 |
| Propranolol Hcl | Propranolol Hcl | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 42 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 11 |
| Terazosin Hcl | Terazosin Hcl | 41 | 11 |
| Acyclovir | Acyclovir | 39 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 39 | 13 |
| Cephalexin | Cephalexin | 38 | 31 |
| Irbesartan | Irbesartan | 38 | 12 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Glipizide Er | Glipizide | 35 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 33 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 16 |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $393.95 · 21 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AREXVY, CAPLYTA, ELIQUIS, FARXIGA, FREESTYLE LIBRE, JARDIANCE, JOURNAVX, Jornay PM, Kerendia, NURTEC ODT, OTEZLA, PENMENVY, REPATHA, REXULTI, SHINGRIX, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error